Updated June 2026 — 11 days remain. If you purchased metformin from Teva, Granules (Avet), or Heritage Pharmaceuticals between July 20, 2015 and June 2, 2020, you have until August 5, 2026 to file a claim in a $5.55 million class action settlement — no documentation required. Simultaneously, a separate and far more significant litigation track is quietly building for metformin users who developed cancer. This article breaks down both tracks, explains who qualifies for each, and tells you exactly what to do before the deadline passes.
The $5.55M Metformin Class Action Settlement: What You Need to Know Before August 5
The metformin lawsuit captioned In re Metformin Marketing and Sales Practices Litigation, filed in the U.S. District Court for the District of New Jersey, has reached a combined settlement of $5.55 million. On May 4, 2026, the court granted preliminary approval to both settlement agreements. Teva Pharmaceuticals is contributing $3 million, while Granules India (marketed under the Avet label) and Heritage Pharmaceuticals are jointly contributing $2.55 million. The settlement also resolves related claims against CVS Pharmacy for its role in selling these products to consumers.
This settlement addresses false-advertising and NDMA contamination claims — meaning defendants allegedly sold metformin products without disclosing that the drugs contained levels of the probable carcinogen N-nitrosodimethylamine (NDMA). Critically, this settlement does NOT cover personal injury or wrongful death claims. If you developed cancer you believe is linked to metformin NDMA exposure, your claim must be pursued on a completely separate legal track, discussed below.
Who Qualifies to File a Claim
You are likely a class member if you meet all three of the following criteria:
- You are a U.S. resident
- You purchased or paid for a metformin-containing drug manufactured or sold by Teva, Granules/Avet, or Heritage Pharmaceuticals (including purchases through CVS)
- Your purchase occurred between July 20, 2015 and June 2, 2020
Individual consumers are not required to submit documentation to file a claim. Claims must be submitted online or postmarked no later than August 5, 2026. Payment will be distributed on a pro-rata basis among all valid claimants, meaning the more people who file, the smaller each individual share. Filing sooner rather than later does not increase your share, but missing the August 5, 2026 deadline means forfeiting your right to any payment entirely.
Key Dates and the Opt-Out Decision
The opt-out deadline is also August 5, 2026 — the same date as the claim filing deadline. This is a critical distinction: if you remain in the settlement class, you permanently release all false-advertising and contamination-related claims against the settling defendants. The court’s final approval hearing is scheduled for August 12, 2026, at which point the settlement will be reviewed and, if approved, become binding on all class members who did not opt out. If you wish to preserve your right to sue Teva, Granules, or Heritage independently — for example, as part of a personal injury claim — you must opt out before August 5. You cannot file a class action claim and opt out simultaneously.
The NDMA Science: Why This Contamination Matters
NDMA (N-nitrosodimethylamine) is classified as a probable human carcinogen by the U.S. Food and Drug Administration and the International Agency for Research on Cancer (IARC). It forms naturally in certain chemical environments and has been discovered as a contaminant in multiple drug classes over the past several years, most notably in ranitidine (Zantac), valsartan, and — relevant here — extended-release metformin.
In 2020, the FDA began testing metformin products and found that some extended-release formulations contained NDMA levels above the agency’s acceptable daily intake limit of 96 nanograms. Several manufacturers voluntarily recalled affected lots. The contamination is believed to result from the degradation of the drug’s chemical components over time, particularly when stored at elevated temperatures.
The central legal question in both the class action and personal injury contexts is whether NDMA exposure at the levels found in recalled metformin products is sufficient to cause cancer in humans. Animal studies have consistently shown NDMA to be carcinogenic at high doses. Epidemiological evidence in humans is more contested, which is why the personal injury litigation remains scientifically and legally complex heading into 2026.
Metformin Lawsuit Data Snapshot: Recalls, Manufacturers, and Litigation Status
| Category | Details |
|---|---|
| Drug at Issue | Metformin hydrochloride extended-release (ER/XR) |
| Contaminant | NDMA (N-nitrosodimethylamine) |
| FDA Recall Period | 2020 (voluntary recalls by multiple manufacturers) |
| Class Action Settlement Amount | $5.55 million combined ($3M Teva; $2.55M Granules/Heritage) |
| Preliminary Approval Date | May 4, 2026 |
| Claim/Opt-Out Deadline | August 5, 2026 |
| Final Approval Hearing | August 12, 2026 |
| Purchase Window Covered | July 20, 2015 – June 2, 2020 |
| Documentation Required | No |
| Personal Injury MDL Status | No consolidated MDL as of mid-2026; cases scattered in federal courts |
The Personal Injury Track: Cancer Victims and MDL Consolidation
Separate from the class action settlement is a growing body of personal injury litigation brought by individuals who took extended-release metformin contaminated with NDMA and subsequently developed cancer. These cases are legally and factually distinct from the class action: they involve allegations of physical harm, not merely economic loss from purchasing a contaminated product.
As of mid-2026, there is no consolidated multidistrict litigation (MDL) for metformin personal injury cancer claims. Unlike the ranitidine litigation — which was centralized before Judge Robin Rosenberg in the Southern District of Florida — metformin cancer cases remain scattered across individual federal courts. This fragmented landscape means plaintiffs and their attorneys must navigate litigation without the structural efficiencies that an MDL typically provides, including coordinated discovery, shared expert witnesses, and bellwether trial scheduling.
This does not mean the personal injury track is dormant. Attorneys across the country are actively investigating and filing individual cases, and the science underlying these claims continues to develop. Should case volume reach a sufficient threshold, a petition to the Judicial Panel on Multidistrict Litigation (JPML) for MDL consolidation remains a possibility. For now, however, personal injury plaintiffs pursuing metformin cancer claims should expect to litigate in their home districts rather than within a centralized federal proceeding.
The cancers most frequently cited in metformin NDMA personal injury litigation include:
- Colorectal cancer
- Liver cancer (hepatocellular carcinoma)
- Stomach cancer (gastric cancer)
- Bladder cancer
- Esophageal cancer
- Kidney cancer (renal cell carcinoma)
- Lung cancer (in non-smokers or light smokers)
- Leukemia and non-Hodgkin’s lymphoma
Plaintiffs asserting personal injury claims must demonstrate more than the purchase of a contaminated product. They must establish general causation (that NDMA at these exposure levels can cause the type of cancer alleged), specific causation (that their particular cancer was caused by their NDMA exposure), and that they used a recalled product during the relevant window. Medical records, pharmacy records, and expert toxicology testimony are typically essential.
Two Tracks, Two Strategies: How to Decide What to Do Right Now
The existence of two parallel legal tracks — the class action and the personal injury litigation — means your optimal strategy depends entirely on your individual circumstances. Here is a framework for thinking through the decision before the August 5, 2026 deadline arrives.
If you purchased covered metformin but did not develop cancer: Filing the class action claim is almost certainly the right move. You will receive a pro-rata share of the settlement fund with no documentation required and no litigation risk. There is no meaningful downside to filing.
If you purchased covered metformin and did develop cancer: This is where the decision becomes more complex. You face a binary choice: file the class action claim and release your false-advertising claims against the settling defendants, or opt out and preserve those claims — alongside your personal injury claims — for independent litigation. Note that filing the class action claim does not automatically release your personal injury claims, since this settlement explicitly excludes personal injury. However, opting out preserves maximum flexibility if your attorney believes your overall case — including economic loss claims — is stronger pursued independently.
If you are unsure whether your cancer may be linked to metformin NDMA exposure: Consult a mass tort attorney before the August 5 deadline. Many personal injury attorneys handling metformin cases offer free consultations and can help you assess whether your medical history, prescription records, and cancer type suggest a viable claim worth pursuing outside the class action settlement.
Frequently Asked Questions: Metformin Lawsuit 2026
Cancers Associated With NDMA Exposure
NDMA is classified as a probable human carcinogen. In animal studies, it has been shown to cause liver, lung, and kidney tumors at elevated doses. In the context of metformin litigation, the cancers most frequently alleged include colorectal, liver, gastric, bladder, esophageal, renal, and certain blood cancers. The strength of the scientific link varies by cancer type, and courts evaluating personal injury claims will scrutinize general causation evidence — including epidemiological studies — closely.
What Personal Injury Plaintiffs Must Establish
To pursue a metformin personal injury cancer claim in 2026, a plaintiff generally must establish:
- Product identification: That they used a metformin product manufactured by a defendant and subject to recall during the relevant period.
- NDMA exposure: That the specific product lot they used contained NDMA above acceptable limits.
- General causation: That NDMA at these exposure levels is capable of causing the type of cancer alleged, supported by expert testimony and peer-reviewed literature.
- Specific causation: That the plaintiff’s cancer was in fact caused by their NDMA exposure, ruling out other contributing factors.
- Damages: Medical expenses, lost income, pain and suffering, and in wrongful death cases, survivor damages.
The Key Defense Argument: FDA Sentinel Data
Defendants in metformin personal injury cases are expected to rely heavily on FDA Sentinel System data — a large-scale pharmacovigilance database — showing no statistically significant increase in cancer rates among metformin users compared to controls. This was a central argument in the ranitidine MDL, where Judge Rosenberg ultimately excluded plaintiffs’ general causation experts and granted summary judgment for defendants. Metformin plaintiffs’ attorneys are aware of this precedent and are working to distinguish their scientific evidence from the ranitidine record.
Can I file both the class action claim and a personal injury lawsuit?
You can file the class action claim and simultaneously pursue a personal injury lawsuit, because this settlement explicitly excludes personal injury and wrongful death claims. However, by participating in the class action, you release your economic loss and false-advertising claims against the settling defendants. If your attorney believes those economic claims have independent value worth preserving — or if you want to sue the settling defendants for all damages in a single unified action — opting out may be advisable. This is a fact-specific determination that warrants legal consultation before the August 5, 2026 deadline.
Does the metformin class action apply to immediate-release metformin?
The FDA’s NDMA concerns and subsequent recalls focused primarily on extended-release (ER or XR) metformin formulations, not immediate-release versions. The class action settlement similarly centers on extended-release products manufactured or sold by the settling defendants during the covered period. If you took only immediate-release metformin, you are unlikely to qualify as a class member. Review the settlement administrator’s eligibility criteria or consult an attorney if you are uncertain about which formulation you used.
What documentation do I need to file the class action claim?
No documentation is required to submit a class action claim. Claimants self-certify that they purchased a covered metformin product during the eligible period. That said, retaining any available records — pharmacy receipts, insurance explanation of benefits statements, prescription records — is advisable if you also intend to pursue a personal injury claim, where documentation of product use is essential.
How much will class action claimants actually receive?
The per-claimant payout depends on the total number of valid claims filed. The $5.55 million settlement fund must cover attorney fees, administrative costs, and distributions to all claimants on a pro-rata basis. In large consumer class actions of this type, individual payouts often range from a few dollars to a few dozen dollars. The exact amount will not be known until after the August 5, 2026 claim deadline closes and claims are tabulated. While the individual recovery may be modest, filing costs claimants nothing and requires no documentation.
Is there a certified MDL for metformin cancer lawsuits in 2026?
No. As of mid-2026, there is no consolidated multidistrict litigation for metformin personal injury cancer claims. Cases are being filed and litigated individually in federal courts across the country. The absence of an MDL means there is no centralized docket, no shared discovery process, and no bellwether trial schedule — all of which typically accelerate resolution in mass tort litigation. Attorneys monitoring case volume believe MDL consolidation remains possible if filings increase significantly, but no petition to the JPML has been granted as of this writing. Individuals with potential personal injury claims should not wait for an MDL to form before consulting an attorney, as statutes of limitations continue to run regardless of litigation structure.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.